{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:55:32Z","timestamp":1791320132630,"version":"4.3.1"},"reference-count":53,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,26]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Virus-specific IgG levels were stable for up to 1 year after CD19-CARTx in adults with durable complete remission. Preexisting humoral immunity may be preserved in adult recipients of CD19-CARTx.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000717","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T12:44:48Z","timestamp":1574253888000},"page":"3590-3601","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":74,"title":["Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy"],"prefix":"10.1182","volume":"3","author":[{"given":"Joshua A.","family":"Hill","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Vaccine and Infectious Disease Division,"},{"name":"Clinical Research Division, and"},{"name":"Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Krantz","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-2677","authenticated-orcid":false,"given":"Kevin A.","family":"Hay","sequence":"additional","affiliation":[{"name":"Clinical Research Division, and"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayan","family":"Dasgupta","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Stevens-Ayers","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6167-1447","authenticated-orcid":false,"given":"Rachel A.","family":"Bender Ignacio","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Vaccine and Infectious Disease Division,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav","family":"Bar","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Clinical Research Division, and"},{"name":"Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Maalouf","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu","family":"Cherian","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Pepper","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley R.","family":"Riddell","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Clinical Research Division, and"},{"name":"Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Clinical Research Division, and"},{"name":"Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Boeckh","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Vaccine and Infectious Disease Division,"},{"name":"Clinical Research Division, and"},{"name":"Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"Turtle","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Clinical Research Division, and"},{"name":"Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,11,19]]},"reference":[{"issue":"3","key":"2019112011422134600_B1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/cpt.392","article-title":"CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies","volume":"100","author":"Turtle","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"2019112011422134600_B2","first-page":"880","article-title":"The promise of chimeric antigen receptor T-cell therapy","volume":"30","author":"Frey","year":"2016","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"2019112011422134600_B3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2016.09.002","article-title":"Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse","volume":"23","author":"Kenderian","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"355","key":"2019112011422134600_B4","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"6","key":"2019112011422134600_B5","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"16","key":"2019112011422134600_B6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"2019112011422134600_B7","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019112011422134600_B8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"9967","key":"2019112011422134600_B9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"303","key":"2019112011422134600_B10","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"224","key":"2019112011422134600_B11","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med"},{"issue":"26","key":"2019112011422134600_B12","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6638","key":"2019112011422134600_B13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/40540","article-title":"Lifetime of plasma cells in the bone marrow","volume":"388","author":"Manz","year":"1997","journal-title":"Nature"},{"issue":"9","key":"2019112011422134600_B14","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.188.9.1691","article-title":"Identification of functional human splenic memory B cells by expression of CD148 and CD27","volume":"188","author":"Tangye","year":"1998","journal-title":"J Exp Med"},{"key":"2019112011422134600_B15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fimmu.2014.00137","article-title":"Immunophenotype of normal and myelomatous plasma-cell subsets","volume":"5","author":"Robillard","year":"2014","journal-title":"Front Immunol"},{"issue":"suppl. 1","key":"2019112011422134600_B16","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1002\/cyto.b.20547","article-title":"Human peripheral blood B-cell compartments: a crossroad in B-cell traffic","volume":"78","author":"Perez-Andres","year":"2010","journal-title":"Cytom B Clin Cytom"},{"issue":"5-6","key":"2019112011422134600_B17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"2019112011422134600_B18","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"2019112011422134600_B19","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2019112011422134600_B20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"2019112011422134600_B21","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2019112011422134600_B22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to the development of hypogammaglobulinemia and infections post-rituximab","volume":"36","author":"Christou","year":"2017","journal-title":"Int Rev Immunol"},{"issue":"2","key":"2019112011422134600_B23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2019112011422134600_B24","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.bbmt.2018.12.068","article-title":"Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation","volume":"25","author":"Kansagra","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"2019112011422134600_B25","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"2019112011422134600_B26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(\u2212)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"issue":"3","key":"2019112011422134600_B27","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2019112011422134600_B28","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1200\/JCO.2008.16.8450","article-title":"Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"27","author":"Raanani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019112011422134600_B29","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/10428190902856824","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019112011422134600_B30","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.bbmt.2018.01.017","article-title":"Choosing wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group\u2019s list of 5 tests and treatments to question in blood and marrow transplantation","volume":"24","author":"Bhella","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019112011422134600_B31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev"},{"issue":"1","key":"2019112011422134600_B32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1472-6963-11-101","article-title":"Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barr\u00e9 syndrome","volume":"11","author":"Winters","year":"2011","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"2019112011422134600_B33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM199107113250202","article-title":"Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia","volume":"325","author":"Weeks","year":"1991","journal-title":"N Engl J Med"},{"issue":"2","key":"2019112011422134600_B34","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome [published corrections appear in Blood. 2015;126(8):1048 and Blood. 2016;128(11):1533]","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019112011422134600_B35","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2019112011422134600_B36","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"2019112011422134600_B37","unstructured":"Blood and Marrow Transplant Clinical Trials Network\n          . Technical manual of procedures, version 3.0. https:\/\/web.emmes.com\/study\/bmt2\/public\/MOP\/BMT%20CTN%20Technical%20MOP%20v3.pdf. Accessed 17 July 2018."},{"issue":"19","key":"2019112011422134600_B38","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of humoral immunity to common viral and vaccine antigens","volume":"357","author":"Amanna","year":"2007","journal-title":"N Engl J Med"},{"issue":"6239","key":"2019112011422134600_B39","doi-asserted-by":"crossref","first-page":"aaa0698","DOI":"10.1126\/science.aaa0698","article-title":"Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome","volume":"348","author":"Xu","year":"2015","journal-title":"Science"},{"issue":"6","key":"2019112011422134600_B40","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood.2019897405","article-title":"Comprehensive viromewide antibody responses by systematic epitope scanning after hematopoietic cell transplantation","volume":"134","author":"Bender Ignacio","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2019112011422134600_B41","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1056\/NEJM199107113250207","article-title":"The use of intravenous immune globulin in immunodeficiency diseases","volume":"325","author":"Buckley","year":"1991","journal-title":"N Engl J Med"},{"issue":"5","key":"2019112011422134600_B42","first-page":"634","article-title":"The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin","volume":"112","author":"Mankarious","year":"1988","journal-title":"J Lab Clin Med"},{"issue":"9351","key":"2019112011422134600_B43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(03)12162-9","article-title":"The common cold","volume":"361","author":"Heikkinen","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"2019112011422134600_B44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"4 suppl","key":"2019112011422134600_B45","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology [published correction appears in J Allergy Clin Immunol. 2006;117(6):1483]","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"2019112011422134600_B46","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction appears in Biol Blood Marrow Transplant. 2010;16(2):294]","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"2019112011422134600_B47","doi-asserted-by":"crossref","first-page":"10899","DOI":"10.1073\/pnas.1821166116","article-title":"Temporal virus serological profiling of kidney graft recipients using VirScan","volume":"116","author":"Isnard","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2019112011422134600_B48","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"key":"2019112011422134600_B49","unstructured":"US Food and Drug Administration\n          . Guidance for industry: safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/safety-efficacy-and-pharmacokinetic-studies-support-marketing-immune-globulin-intravenous-human. Accessed 4 March 2019."},{"issue":"23","key":"2019112011422134600_B50","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1056\/NEJMp1905099","article-title":"Measles in 2019 - going backward","volume":"380","author":"Paules","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"2019112011422134600_B51","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019112011422134600_B52","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019112011422134600_B53","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/1521-4141(200103)31:3<939::AID-IMMU939>3.0.CO;2-I","article-title":"Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life","volume":"31","author":"Pihlgren","year":"2001","journal-title":"Eur J Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/22\/3590\/1541170\/advancesadv2019000717.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/22\/3590\/1541170\/advancesadv2019000717.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T12:45:12Z","timestamp":1574253912000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/22\/3590\/428810\/Durable-preservation-of-antiviral-antibodies-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":53,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019,11,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000717","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,19]]}}}